CDEK
← All drugs Report issue

mart-1 peptide pulsed dendritic cells

Vaccineexperimental

Clinical trial activity

35 trials · 20 clinical orgs · 0 marketing orgs

Phase 1
14
Phase 2
22
Phase 3
1
Phase 4
0

Earliest trial started Jan 1, 1997 (NCT00002952)

Timeline

1990s

  1. Jan 1, 1997

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 1998

    Earliest Phase 2 Sponsor(trial)

2000s

  1. Jan 1, 2002

    Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • dendritic cell-mart-1 peptide vaccine
  • mart-1
  • mart-1 antigen
  • mart-1 peptide pulsed dendritic cells

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT02320305N/AJan 1, 2015Mayo Clinic, National Cancer Institute (NCI)
NCT01748747N/AOct 1, 2012Mayo Clinic, National Cancer Institute (NCI)
NCT01307618Phase 2Feb 1, 2011National Cancer Institute (NCI), University of Chicago
NCT01176461Phase 1Aug 1, 2010Bristol-Myers Squibb, Medarex, National Cancer Institute (NCI), University of South Florida
NCT00910650Phase 2Oct 1, 2009California Institute of Technology, National Cancer Institute (NCI), University of California, Los Angeles, University of Connecticut, University of Southern California
NCT00923195Phase 2Dec 1, 2008National Cancer Institute (NCI), National Institutes of Health (NIH)
NCT00706992Phase 2Jun 1, 2008National Cancer Institute (NCI), National Institutes of Health (NIH)
NCT00470015Phase 1Mar 1, 2007Mayo Clinic, National Cancer Institute (NCI)
NCT00295958Phase 2Dec 1, 2005National Cancer Institute (NCI), National Institutes of Health (NIH)
NCT00303836Phase 2Nov 1, 2005National Cancer Institute (NCI), National Institutes of Health (NIH)
NCT00091338Phase 1Aug 1, 2004National Cancer Institute (NCI), National Institutes of Health (NIH)
NCT00091104Phase 1Jul 1, 2004National Cancer Institute (NCI), National Institutes of Health (NIH)
NCT00089063Phase 2Jun 1, 2004National Cancer Institute (NCI), University of Southern California
NCT00334776Phase 2Oct 1, 2003National Cancer Institute (NCI), University of Southern California
NCT00059475Phase 2Apr 1, 2003National Cancer Institute (NCI), National Institutes of Health (NIH)
NCT00039325Phase 1/Phase 2 (Phase 2)Mar 1, 2002National Cancer Institute (NCI), National Institutes of Health (NIH), University of California, Los Angeles
NCT00036816Phase 3Feb 1, 2002European Organisation for Research and Treatment of Cancer, Université catholique de Louvain, University of Copenhagen
NCT00031733Phase 2Feb 1, 2002National Cancer Institute (NCI), University of Southern California
NCT00037037Phase 1Oct 1, 2001Herbert Irving Comprehensive Cancer Center, National Cancer Institute (NCI)
NCT00025181Phase 1Oct 1, 2001National Cancer Institute (NCI), University of Southern California
Showing 20 of 35 trials
Page 1 / 2

Organizations

Research & Development (20)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
National Cancer Institute (NCI)Government331531997
National Institutes of Health (NIH)Government12221997
University of Southern CaliforniaAcademic/Hospital7521999
Mayo ClinicAcademic/Hospital4322000
University of California, Los AngelesAcademic/Hospital3321997
University of ChicagoAcademic/Hospital2111997
Baylor UniversityAcademic/Hospital1111999
Bristol-Myers SquibbFor profit1012010
California Institute of TechnologyAcademic/Hospital1012009
Eastern Cooperative Oncology GroupAcademic/Hospital1112000
European Organisation for Research and Treatment of CancerAcademic/Hospital1112002
GenzymeFor profit1112000
Herbert Irving Comprehensive Cancer CenterAcademic/Hospital1112001
MedarexFor profit1012010
Université catholique de LouvainAcademic/Hospital1012002
University of ConnecticutAcademic/Hospital1012009
University of CopenhagenAcademic/Hospital1012002
University of PennsylvaniaAcademic/Hospital1011999
University of PittsburghAcademic/Hospital1012000
University of South FloridaAcademic/Hospital1112010
20 organizations
Page 1 / 1